M-CENK

BIOLOGICAL2 trials

Sponsors

ImmunityBio, Inc.

Conditions

High-risk Prostate CancerPlatinum-resistant Ovarian Cancer

Phase 2

A Phase 2, Open-label, Single-arm Study Of Autologous M-CENK Adoptive Cell Therapy And N-803 (IL-15 Superagonist) In Combination With Gemcitabine In Participants With Recurrent Platinum-Resistant High-Grade Ovarian Cancer

RecruitingNCT06710288

ImmunityBio, Inc.Platinum-resistant Ovarian Cancer

Start: 2024-11-06End: 2027-05-01Target: 20Updated: 2026-07-01

Immunotherapy Before and After Surgery

WithdrawnNCT06765902

ImmunityBio, Inc.High-risk Prostate Cancer

Start: 2025-12-15End: 2031-06-30Updated: 2026-05-05